Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tonix Pharma ( (TNXP) ) has shared an announcement.
On September 18, 2025, Tonix Pharmaceuticals announced the completion of a Type B Pre-IND meeting with the FDA for its TNX-102 SL product candidate aimed at treating major depressive disorder. The FDA’s feedback was positive, suggesting that the proposed long-term safety data collection plan is reasonable, which may streamline the development path. Tonix plans to file an Investigational New Drug application in the fourth quarter of 2025 and expects to enter Phase 2 clinical trials soon after, potentially expanding the therapeutic indications of TNX-102 SL.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall score is driven by strong corporate events, particularly the FDA approval of Tonmya, which significantly boosts its market potential. However, challenges in profitability and valuation weigh down the score. Mixed technical indicators suggest cautious optimism.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development of innovative therapeutics. The company is primarily engaged in creating treatments for central nervous system disorders, with a market focus on unmet medical needs.
Average Trading Volume: 1,456,977
Technical Sentiment Signal: Sell
Current Market Cap: $242.9M
See more data about TNXP stock on TipRanks’ Stock Analysis page.